MEDESIS PHARMA S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.4 EUR | -2.10% |
|
-10.83% | +61.29% |
| 2023 | Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2023 | MEDESIS : Invest Securities confirms its recommendation | CF |
| Sales 2021 | 95.73K 102K | Sales 2022 | 197K 211K | Capitalization | 8.68M 9.28M |
|---|---|---|---|---|---|
| Net income 2021 | -2M -2.14M | Net income 2022 | -2M -2.14M | EV / Sales 2021 | 219 x |
| Net cash position 2021 | 1.61M 1.72M | Net Debt 2022 | 1.08M 1.15M | EV / Sales 2022 | 49.4 x |
| P/E ratio 2021 |
-8.52
x | P/E ratio 2022 |
-3.16
x | Employees | 10 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 80.97% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -2.10% | ||
| 1 week | -10.83% | ||
| Current month | -8.20% | ||
| 1 month | -6.04% | ||
| 3 months | +75.00% | ||
| 6 months | +74.13% | ||
| Current year | +61.29% |
1 week
1.40
1.57
1 month
1.311.58
Current year
0.752.40
1 year
0.752.67
3 years
0.7510.10
5 years
0.7518.00
10 years
0.7518.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 03-04-02 | |
Solene Guilliot
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Mario Alcaraz
SEC | Corporate Secretary | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 19-06-11 | |
Robert Alonso
BRD | Director/Board Member | - | 22-10-26 |
Walt Linscott
BRD | Director/Board Member | 63 | 22-10-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.4 | -2.10% | 2,682 |
| 24-04-25 | 1.43 | -5.92% | 668 |
| 24-04-24 | 1.52 | 0.00% | 164 |
| 24-04-23 | 1.52 | +4.11% | 258 |
| 24-04-22 | 1.46 | -7.01% | 4,375 |
Real-time Euronext Paris, April 26, 2024 at 08:19 am EDT
More quotes
Medesis Pharma S.A. is specialized in the research and development, based on a breakthrough technology (AONYS®) for the delivery of therapeutic molecules, of drugs to treat diseases for which there is no effective treatment.
The company's portfolio includes a drug candidate used to optimize cancer radiotherapy, 2 drug candidates used in the treatment of neurodegenerative diseases (Alzheimer's disease and Huntington's disease) and 2 drug candidates used in the treatment of radioactive contamination following a civil or military nuclear accident (Plutonium decorporation and cesium decorporation).
| 1st Jan change | Capi. | |
|---|---|---|
| +61.29% | 6.62M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ALMDP Stock
